Elsevier

The Lancet

Volume 345, Issue 8954, 8 April 1995, Pages 877-882
The Lancet

Australian collaborative trial of antenatal thyrotropin-releasing hormone (ACTOBAT) for prevention of neonatal respiratory disease

https://doi.org/10.1016/S0140-6736(95)90007-1Get rights and content

Abstract

The addition of thyrotropin-releasing hormone (TRH) to antenatal glucocorticoid treatment of women at risk of preterm delivery has been reported to lower the risk of respiratory distress syndrome (RDS) in the infant. We have assessed the efficacy of 200 μg TRH in a multicentre randomised trial. 1234 women at 24 weeks to 31 weeks 6 days of gestation with a singleton or twin pregnancy and at risk of preterm delivery were randomly allocated to groups receiving 200 μg TRH or placebo intravenously every 12 h up to a maximum of four doses. Randomisation was stratified by duration of gestation and centre. All women received glucocorticoids. Clinical outcome is known for 1231 women and their 1397 infants. The frequencies of the main prespecified study outcomes RDS (relative risk 1·17 [95% Cl 1·00-1·36], p=0·05) and need for ventilation (1·15 [1·01-1·31], p=0·04) were higher in TRH-group infants than in control infants. The excess risk in the TRH group was greater in infants who were born more than 10 days after treatment. Multivariate analysis adjusting for duration of gestation at randomisation, time from randomisation to delivery, parity, history of perinatal death, and infant's sex did not affect the risk estimates. TRH administration was associated with increased risks of maternal nausea, vomiting, lightheadedness, and a rise in blood pressure to 140/90 mm Hg or higher. Antenatal TRH given with glucocorticoids to women at high risk of preterm delivery is associated with maternal and perinatal risks and cannot be recommended for widespread clinical use.

References (24)

  • Ra Ballard et al.

    Respiratory disease in very-low-birthweight infants after prenatal thyrotropin-releasing hormone and glucocorticoid

    Lancet

    (1992)
  • Db Knight et al.

    A randomised controlled trial of antepartum thyrotropin-releasing hormone and betamethasone in the prevention of respiratory disease in preterm infants

    Am J Obstet Gynecol

    (1994)
  • Jc Schellenberg et al.

    Synergistic hormonal effects on lung maturation in fetal sheep

    J Appl Physiol

    (1988)
  • Gc Liggins et al.

    Synergism of cortisol and thyrotropin releasing hormone in lung maturation in fetal sheep

    J Appl Physiol

    (1988)
  • Wi Morales et al.

    Fetal lung maturation: the combined use of corticosteroids and thyrotropin-releasing hormone

    Obstet Gynecol

    (1989)
  • H. Jikihara et al.

    Maternal administration of thyrotropin-releasing hormone for prevention of neonatal respiratory distress syndrome

    Proceedings of 6th Congress of the Federation of the Asia-Oceania Perinatal Societies.

    (1990)
  • F. Althabe et al.

    Controlled trial of prenatal betamethasone plus TRH vs betamethasone plus placebo for prevention of RDS in preterm infants

    Pediatr Res

    (1992)
  • J. Ceriani et al.

    Controlled trial of prenatal betamethasone (B) plus TRH for prevention of respiratory distress syndrome (RDS) in preterm infants

    Pediatr Res

    (1992)
  • R. Hall et al.

    Thyroid-stimulating hormone response to synthetic thyrotropin-releasing hormone in man

    BMJ

    (1976)
  • Pj Snyder et al.

    Response to thyrotropin-releasing hormone (TRH) in normal man

    J Clin Endocrinol Metab

    (1972)
  • Cited by (88)

    • OGT-related mitochondrial motility is associated with sex differences and exercise effects in depression induced by prenatal exposure to glucocorticoids

      2018, Journal of Affective Disorders
      Citation Excerpt :

      Glucocorticoids (GCs) are known to treat preterm delivery in pregnant women (ACTOBAT Study Group, 1995); however, prenatal exposure to GCs has been found to trigger abnormal behaviors and deleterious neurological effects on offspring both in animals and in humans (Braithwaite et al., 2015; Kim et al., 2015).

    • Trials with Thyroid Hormone in Preterm Infants: Clinical and Neurodevelopmental Effects

      2008, Seminars in Perinatology
      Citation Excerpt :

      Also, because amniotic administration is an invasive procedure, while maternal administration of glucocorticoids is a proven and effective therapy to induce lung maturation, investigations might not have been stimulated to set up these trials. A combination therapy of maternal administration of thyrotropin-releasing hormone and glucocorticoids was not found to be effective in improving respiratory outcomes of premature infants.31 Thyroid hormones increase cardiac inotropy and chronotropy.13,32

    • Respiratory Disorders of the Newborn

      2008, Pediatric Respiratory Medicine
    • Antenatal magnesium sulphate neuroprotection in the preterm infant

      2007, Seminars in Fetal and Neonatal Medicine
      Citation Excerpt :

      Several recent randomised controlled trials (RCTs) of different therapies, launched because of promising data from animal studies or earlier smaller human studies, have proved to be unsuccessful at improving long-term outcomes for very preterm infants. One example is antenatal thyrotropin-releasing hormone (TRH), which not only failed to reduce the rate of respiratory distress when it was expected to do so,13 but was also associated with adverse longer-term outcomes in the babies exposed to TRH in the uterus.14 Another example is prophylactic indometacin, which reduced the rate of major intraventricular haemorrhage in an earlier smaller study15 but did not improve long-term outcome in a much larger RCT.16

    • Neonatal respiratory distress syndrome after repeat exposure to antenatal corticosteroids: a randomised controlled trial

      2006, Lancet
      Citation Excerpt :

      This study is registered as an International Standard Randomised Controlled Trial, number ISRCTN48656428. A sample size of 980 women was needed to detect a 25% reduction in the risk of respiratory distress syndrome (the main endpoint of the trial) from 30%20 to 22·5% with 80% power (β=0·20) at a two-sided significance level of 5% (α=0·05). Data were reviewed twice by the independent data monitoring committee who were not aware of treatment-group allocation.

    View all citing articles on Scopus
    1

    ACTOBAT participants listed at end of paper

    View full text